APA (7th ed.) Citation

Michaeli, D., Mills, M., Michaeli, C. T., Miracolo, A., & Kanavos, P. (2022). Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA: Phase III studies. Investigational new drugs, 40(4), . https://doi.org/10.1007/s10637-022-01227-5

Chicago Style (17th ed.) Citation

Michaeli, Daniel, Mackenzie Mills, Christoph T. Michaeli, Aurelio Miracolo, and Panos Kanavos. "Initial and Supplementary Indication Approval of New Targeted Cancer Drugs by the FDA, EMA, Health Canada, and TGA: Phase III Studies." Investigational New Drugs 40, no. 4 (2022). https://doi.org/10.1007/s10637-022-01227-5.

MLA (9th ed.) Citation

Michaeli, Daniel, et al. "Initial and Supplementary Indication Approval of New Targeted Cancer Drugs by the FDA, EMA, Health Canada, and TGA: Phase III Studies." Investigational New Drugs, vol. 40, no. 4, 2022, https://doi.org/10.1007/s10637-022-01227-5.